Category Archives: Actos

Featured Stories

Actos Whistleblower Lawsuit Questions Avandia Researcher's Financial Ties to Takeda

A prominent researcher has been implicated in an alleged cover-up of Actos side effects, according to a report from TheHeart.org. An Actos whistleblower lawsuit unsealed earlier this year has alleged financial connections between the Cleveland Clinic’s Dr Steven Nissen and the maker of Actos “should be considered when analyzing Actos’s ...

Read More

DeflateGate’s Effects Impact Legal Gambling & the Economy

DeflateGate’s-Effects-Impact-Legal-Gambling-and-the-Economy

The NFL has initiated a probe into the New England Patriots following allegations that the team intentionally used overly deflated footballs.

Read More

Image Source: saidaonline.com

Sleep Aids Can Increase Alzheimer’s Risk

A new study has found that over-the-counter sleeping aids and anti-allergy medicines can increase the risk of Alzheimer’s disease.

Read More

Study Finds Metal-on-Metal Hip Implants Associated with High Incidence of Pseudotumors

Yet another study is adding to concerns about the potential dangers associated with metal-on-metal hip implants. The study, published in the Journal of Bone and Joint Surgery, found that large diameter metal-on-metal total hip replacement may be associated with a substantially higher incidence of pseudotumor formation.

Read More

Johnson & Johnson Facing More Metal-on-Metal Hip Implant Woes, as DePuy Pinnacle Complaints Rise

Having already spent around $3 billion on its DePuy Orthopaedics ASR hip implant recall, Johnson & Johnson is facing another potential debacle involving a metal-on-metal version of its Pinnacle Hip Replacement System. According to a report from Reuters, Johnson & Johnson and its DePuy unit already face some 1,600 metal-on-metal ...
FDA Urged to Ban Powdered Caffeine

FDA Urged to Ban Powdered Caffeine

Pennsylvania Senator Robert Casey has written to the Food and Drug Administration (FDA) to urge the agency to ban powdered caffeine, a dietary supplement.

Read More

FDA Metal-On-Metal Hip Replacement Investigation Is Flawed, Researchers Say

The U.S. Food & Drug Administration’s (FDA) metal-on-metal hip replacement investigation is flawed, according to researchers.

Read More

Stryker Issues Voluntary Recall for Rejuvenate Modular and ABG II Hip Implant Components

Stryker Orthopedics is recalling two metal-on-metal hip implant components, its Rejuvenate Modular and ABG II modular-neck hip stems. According to a notice posted on Stryker’s website, risks associated with the Rejuvenate Modular and ABG II modular-neck hip stems include the potential for fretting and/or corrosion at or about ...

Read More

Bleeding Side Effects of Pradaxa, Xarelto Have Some Doctors Concerned

Some heart doctors are raising concerns about a new class of heart drugs that include Pradaxa. Recently, a number of doctors interviewed by Reuters said they were hesitant to prescribe Pradaxa, as well as another blood thinner called Xarelto, because of concerns regarding the risk of stroke, serious bleeding ...

Read More

Metal-on-Metal Hip Implant Lawyer Takes Issue with Statements Made by DePuy Orthpaedics Official During FDA Meeting

An attorney with a national law firm that represents victims of alleged metal-on-metal hip implant injuries has expressed dismay at some statements made last week regarding the regulation of all-metal hip replacement devices by an official with DePuy Orthopaedics. According to Daniel Burke, Senior Litigation Counsel at Parker ...

Read More

Controversial Diabetes Drug Actos Still on the Market

Controversial Diabetes Drug Actos Still on the Market

Though research has shown an association between the type 2 diabetes drug Actos and serious side effects including bladder cancer, heart failure, liver failure, and bone fractures, the Food and Drug Administration (FDA) has stopped short of recalling Actos. Actos … Continue reading

Posted in Actos, Pharmaceuticals | Tagged , , , , |

Actos Makers Continue to Face Bladder Cancer Claims

Actos Makers Continue to Face Bladder Cancer Claims

Lawsuits continue to be filed over Actos, a type 2 diabetes drug developed by Takeda and Eli Lilly. Plaintiffs in the litigation allege that Actos contributed to bladder cancer. Drug makers are accused of failing to disclose this risk to … Continue reading

Posted in Actos, Pharmaceuticals | Tagged , , , , |

Actos Bladder Cancer Cases Continue to be Filed

In the continuing controversy over the link between the type 2 diabetes drug Actos (pioglitazone) and bladder cancer, a new lawsuit was filed in June 2016 by a man who was diagnosed with bladder cancer after taking Actos for six … Continue reading

Posted in Actos, Defective Products, Health Concerns, Pharmaceuticals |

Diabetes Drug Pioglitazone Linked to Increased Risk of Bladder Cancer

An increased risk of bladder cancer has been uncovered following a large population-based study concerning patients who take the diabetes drug pioglitazone known to most as Actos, the Renal and Urology News reports. Pioglitazone is a single-ingredient product sold under … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

$2.4 Billion Settlement Announced in Actos Bladder Cancer Cases

$2.4B Settlement Announced in Actos Bladder Cancer Cases

On Tuesday, Takeda Pharmaceuticals announced a settlement that could go as high as $2.7 billion to resolve thousands of lawsuits from patients and their families who claim the diabetes drug Actos (pioglitazone) caused their bladder cancer. The New York Times … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals | Tagged , , , |

Jury Awards $2 Million in Actos Case

Late last week, a Pennsylvania jury ordered Takeda Pharmaceuticals to pay more than $2 million to a woman who claimed her bladder cancer was caused by the company’s diabetes drug Actos (pioglitazone). The jury found that Takeda officials failed to … Continue reading

Posted in Actos, Legal News, Pharmaceuticals |

Actos Litigation Update: Takeda Pharmaceutical Company, Eli Lilly and Company Ordered to Pay $9 Billion in Punitive Damages

Takeda Pharmaceutical Company and Eli Lilly and Company were just ordered to pay a total of $9 billion in punitive damages over Actos litigation involving bladder cancer allegations. Takeda and Eli Lilly lost a bid to have the Actos trial … Continue reading

Posted in Actos, Pharmaceuticals |

Jury Deliberations Begin in Nevada Actos Trial

On Tuesday, a jury in the Las Vegas began deliberating to determine whether Takeda Pharmaceuticals is liable for the bladder cancer of two women, both in their 80s, who were diagnosed with the disease after taking the diabetes drug Actos … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals |

Judge May Punish Lawyers for Misconduct in Actos Trial

Las Vegas district judge Kerry Earley is considering a request to punish lawyers for misconduct during a civil trial over the cancer risks associated with Takeda Pharmaceuticals’ diabetes drug Actos. On Thursday, Judge Earley heard arguments from an attorney representing … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals |

Takeda May Not Pay Eli Lilly’s Portion of Actos Injury Lawsuit

Eli Lilly & Co. has indicated that its former marketing partner, Takeda Pharmaceutical Co., may not pay Lilly’s share of a recent United States jury verdict that ordered Takeda and Lilly to pay $9 billion in punitive damages in a … Continue reading

Posted in Actos, Legal News, Pharmaceuticals |

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.